🇺🇸 FDA
Pipeline program

Ritlecitinib tosilate, Placebo for pf-06651600-15, 100 mg, Placebo for pf-06651600-15, 50 mg, LORATADINE, Ritlecitinib Tosilate

B7981118

Phase 2 small_molecule active

Quick answer

Ritlecitinib tosilate, Placebo for pf-06651600-15, 100 mg, Placebo for pf-06651600-15, 50 mg, LORATADINE, Ritlecitinib Tosilate for CHRONIC SPONTANEOUS URTICARIA is a Phase 2 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Pfizer Ireland Pharmaceuticals Unlimited Company
Indication
CHRONIC SPONTANEOUS URTICARIA
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials